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￿ Centre for Health EconomicsAbstract
Age related macular degeneration (AMD) is the leading cause of blindness in the
United Kingdom and the rest of the western world.  It occurs in 15% to 30% of
individuals over 75 years of age.  About 15% of these patients develop a more
aggressive wet form of the disease that causes severe loss of vision.  This report
contains estimates of the benefits of photodynamic therapy (PDT) with verteporfin
therapy using a modeling approach based on clinical trial data.
While this report covers only the effects of the treatment, the model built was
customizable so that it could be populated with local cost data.  This made it possible
to use the model to help inform local formulary decisions.CHE Discussion Paper 187  1
Introduction
Age related macular degeneration (AMD) is the leading cause of blindness in the
United Kingdom and western world.  It occurs in about 30% of individuals over 75
years of age.  About 15% of these patients develop a more aggressive wet form of
the disease, which causes severe loss of vision.  This has significant public health
implications as affected patients experience severe visual loss, suffer chronic
morbidity and also require the provision of long-term social medical support services.
A treatment that prevents the loss of vision associated with wet AMD could
potentially make significant quality of life improvements for patient suffering from
AMD and also save resources from both the medical and social services sector.
Photodynamic therapy (PDT) involves the intravenous administration of  verteporfin,
a photosensitizing agent, and application of a light source (laser) to area of the eye
affected by AMD.  The non-thermal laser used activates the verteporfin and causes
occlusion of the neovascular vessels associated with wet AMD.
Objective
The objective of this research is to quantify the potential long-term benefits of PDT
with verteporfin (Visudyne￿, Novartis AG, Switzerland) in the treatment of AMD.
This is accomplished by employing modeling, using data from a 2-year randomized
clinical trial.
We also present an appendix that uses follow-up data for an additional year (on the
treated group only) made available after the 2-year trial ended.
Data Source
This analysis used data from the Treatment of AMD with PDT (TAP) clinical
trial.(Bressler, 2001)  The TAP clinical trial included patients presenting with
subfoveal choroidal neovascularization (CNV) lesions due to AMD, having a greatest
linear dimension of <5,400 um, evidence of classic CNV, and best corrected visual
acuity between 20/40 and 20/200.  There were 609 patients in total; 402 were
randomized to treatment with verteporfin (6mg/m
2) and 207 randomized to placebo
(D5W), both infusions followed by 50 J/cm
2 of light at 689 nm after 15 minutes of
starting the infusion.  At each follow-up visit of 3 months, patients were retreated with
the baseline regimen if fluorescein leakage from CNV was identified on angiography.
One eye from each patient was enrolled in the study.
The primary study outcome was moderate vision loss defined as loss of <3 lines of
visual acuity (15 letters).  Of those on verteporfin, 53% lost <3 lines of vision
compared to 38% of placebo treated eyes (p<0.001).  The outcome of avoidance of
severe vision loss (defined as a loss of <6 lines, or <30 letters) was experienced by
82% of those on verteporfin and 70% of those on placebo (p<0.001).  The study
results indicate that more individuals in the placebo group had a visual acuity at 24
months that was < 20/200 compared to those in the verteporfin group (55.2% versus
41.0%; p<0.001).
Prospectively planned subgroup analysis was done based on the presence of classic
CNV in the lesion being treated.  Those with minimally classic lesions (>0% and
<50% out of the entire area of the lesion being classic) were found to have no
clinically meaningful difference with respect to the primary visual acuity outcome;
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lesions lost fewer than 15 letters (p0.58).  Those patients with predominately classic
lesions (at least 50% of the entire lesion being classic) fared much better with
verteporfin treatment on the primary visual acuity outcome; 59% of those on
verteporfin versus 31% of those on placebo lost <15 letters.
Since the approved labeling for PDT with verteporfin indicates that only those with
predominately classic CNV should be treated, this analysis focuses on the subset of
243 patients with that particular form of disease.
Modelling the Benefits of PDT with Verteporfin
We used the clinical trial data to estimate the benefits for two time periods; two years
(within-trial estimate), and over five years.  In order to make estimates of the effect
that treatment would have on disease progression we used a Markov process.  The
health states used in the Markov model came directly from clinical trial
measurements.  Visual acuity (measured during the clinical trial as a Snellen Score)
was used as the indicator of a patient’s disease severity.  The health states used are
shown below.  Death is included as a health state due to the advanced age of the
cohort. Costs of care and health state valuations for both groups (treatment and
placebo) can be attached to each of these health states in order to calculate
incremental costs and benefits of treatment with verteporfin.
















Vision = worse than 20/800
Death
We used survival analysis to estimate transition probabilities from the clinical trial
data to populate the Markov model.  These transition probabilities were estimates of
the daily probability of moving to a lower state of visual acuity. We used survival
analysis regression to estimate time (days) to a drop in one level of visual acuity,
controlling for baseline visual acuity, gender and age.  Specifically, there are 15
levels of visual acuity possible in the trial (from 20/40 to > 20/800).  Therefore a
person starting at the best level of acuity would need to experience 14 Snellen
‘drops’ to get to the worst level of acuity in the trial.  Likewise, a person with a starting
acuity of 20/100 would get to 20/200 in three Snellen drops.  Using the regression
results, the predicted time to transition to a state n Snellen levels lower was
calculated, controlling for baseline visual acuity level.  The predicted transition ratesCHE Discussion Paper 187  3
(hazards) were then used to calculate the probability of progression for verteporfin
and placebo.
We used an accelerated life model with a Weibull parametric hazard to estimate the
impact of treatment controlling, for baseline severity and other potential confounders.
The regressions performed were accelerated failure time models with an assumed
Weibull distribution for the hazard, the hazard being the conditional probability of a
given level of transition.  The survival function from this hazard can be written as:
where l is the Weibull scale parameter, modelled as a loglinear function of the
regressors (i.e. l=exp(-b bx)), and a is the Weibull shape parameter, which determines
whether the hazard slopes up or down.  The time component (t) was varied to
produce estimates of the hazard for points in time outside the trial.
One practical difficulty with the above approach is that measurement of disease
severity is not done continuously, but rather at discrete intervals; every 3 months in
the case of the clinical trial used here.  Since we were interested in predicting time to
progression based on the number of lines of visual acuity lost (Snellen drops), we
would have liked to have known precisely when the event (loss of a line of visual
acuity) occurred.  To overcome this issue, we used linear interpolation to predict the
date of progression when a person lost more than one line of vision between visits.
For example, suppose a person experiences a loss of vision equivalent to 2 Snellen
drops between their 3-month follow-up visits (eg. from 20/64 to 20/100).  This person
has entered one other health state (specifically, 20/80) during those 3 months, but we
don’t know precisely when.  Our estimate was based on a linear assumption that the
person spent an equal amount of time in each health state moved through in
between visits.
Outcome Measures
There are two principal outcome measures used in the analysis; vision years gained,
and quality adjusted life years gained.
Vision years gained
Vision years gained was calculated as the amount of time spent above a visual acuity
level of 20/200.  This level of vision was chosen as the cut-off as it had been used in
many previous studies, and because it is commonly considered ‘legal blindness’ in
many countries.
The Kaplan-Meier plot from the clinical trial for time to visual acuity of 20/200 (34
letters or less) is shown below.  This plot shows the data for patients with
predominately classic CNV.  Patients treated with PDT with verteporfin have a
statistically significantly longer time to progression to vision of 20/200 (p<0.001).  For
the economic analysis, the measure of interest from the Kaplan-Meier plot is the area
between the PDT with verteporfin curve and the placebo curve.  This area reveals
the incremental number of months (over the 2-year trial period) spent above 20/200
by those treated with PDT with verteporfin.  This incremental number of months,
converted to the proportion of a year, is the vision years gained by PDT with
verteporfin.  In the plot shown, this is about 141 days, or 0.39 vision years.    We
used a model to estimate this area so that extrapolations could be made outside the
duration of the clinical trial.  A comparison of the actual data (below) to our modelled
estimates is discussed later.
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Quality of life estimates were from a study undertaken by Brown, et al. (2000). These
estimates were obtained using valuations from 80 patients with AMD, using time
trade-off methods to obtain utility estimates for best-corrected visual acuity.  The
Brown study provided utility estimation for various levels of visual acuity, so we were
able to map utilities from their study to the clinical trial data through visual acuity.
Estimates of quality adjusted life years were obtained from the model through
weighting the time spent in each visual health state by the utility as calculated by
Brown. The study by Brown et al did not use exactly the same visual acuity
designations as were used in the TAP study, so some slight adaptation was
necessary.  The categories from the Brown study were: group 1) 20/20 to 20/25;
group 2) 20/30 to 20/50; group 3) 20/60 to 20/100; group 4) 20/200 to 20/400; and
group 5) the ability to count fingers to light perception.  The utilities they found were,
group 1) 0.89 (95% CI, 0.82-0.96); group 2, 0.81 (95% CI, 0.73-0.89); group 3, 0.57
(95% CI, 0.47-0.67); group 4, 0.52 (95% CI, 0.38-0.66); and group 5, 0.40 (95% CI,
0.29-0.50).  The TAP trial did not include anyone with vision better than 20/40, so
group 1 of the Brown study was not used.
For the extrapolated analysis (using the Markov model) results within the model were
discounted at a rate of 6% for costs and 2% for benefits following recommendations
from the HM Treasury (1991).
Model Calibration
In order to test the reliability of the Markov model predictions, we compared the
underlying clinical trial data with the predicted outcomes.  The model predicts gains
in vision years based on a given baseline visual acuity level.  In order to compare the
model predictions to the actual data, we used an average of the model predictions,
weighted by the proportion of people represented in the trial at each visual acuity
level.  To facilitate the comparison with the clinical trial data, transition to the death
state was not allowed, and the results are undiscounted.  As previously mentioned,
the clinical trial showed a vision year gain of about 0.39 years.  The model predicted
a gain of 0.34 years over the 2-year period, or 87% of the actual gain.  The model
thus appears to supply conservative estimates over the trial period. While it is notCHE Discussion Paper 187  5
possible to say for certain, the model may also thus give conservative estimates
when extrapolating outside the clinical trial.
Assumptions in the Model
Retreatments
Patient follow-up is suggested at 3-month intervals for those receiving PDT with
verteporfin treatment.  In the clinical trial, all patients in the verteporfin-treated group
received a baseline treatment, followed by further treatment if there was evidence of
leakage from CNV on fluorescein angiography.   The trial collected data on the
proportion of patients who received treatment over 2 years.  In order to estimate the
proportion of patients continuing to receive treatment after the 2-year trial follow-up,
we used a simple linear trend based on the previous (2 year) data as shown below.
This extrapolation predicted that no patients would be treated after 3 years.
Table 2: Retreatments





Month 3 0.95 1.95
Month 6 0.81 2.76
Month 9 0.69 3.45
Month 12 0.57 4.02
Month 15 0.56 4.58
Month 18 0.51 5.09
Month 21 0.39 5.48
Month 24 0.29* 5.77*
Month 27 0.20* 5.97*
Month 30 0.12* 6.09*
Month 33 0.03* 6.12*
* Proportion estimated using least squares best fit line
Treated Eye
Another assumption in the model is that the better seeing eye is treated eye.   Since
AMD is a progressive, bilateral disease, this assumption implies that the results are
applicable, say, in a situation where treatment is initiated when the patient has
bilateral AMD involvement.  The better seeing eye will often be the second eye
involved.
Treatment Alternative
The 12-month results from the TAP Investigation demonstrated that approximately
92% of the patients eligible for PDT with verteporfin therapy would not have been
eligible for treatment with laser photocoagulation.(Miller et al. 1999) The majority of
the lesions that are eligible for laser photocoagulation are extrafoveal, whereas the
patients included in the TAP Investigation had subfoveal CNV. The proposed
guidelines for clinical use of PDT with verteporfin are expected to result in the
treatment of a similar patient population, the great majority of whom would also be
ineligible for laser photocoagulation according to the MPS treatment
guidelines.(Macular-Photocoagulation-Study-Group, 1991)  Therefore, the best6   Modelling the long term benefits of PDT with verteporfin for AMD
assessment of the costs and benefits is obtained by comparing verteporfin therapy
with no treatment, rather than by comparing it with laser photocoagulation.
Improvements in Vision
A conservative assumption was applied, in that although the clinical trial showed
some improvement in visual acuity associated with verteporfin treatment, the Markov
process used here did not allow for improvement in vision.  Rather, once a person
had crossed into a given level of acuity, they stayed at that level until worsening of
their visual acuity.  Mortality data for the model was based on the UK population
death rates.
Survival Analysis Results
The results of the survival analysis – upon which the Markov transition probabilities
were based –  are shown below.  The regression shown here is for a drop of one
Snellen visual acuity state.  In the Markov model, transitioning from one state of
visual health to the next worse state of visual health (i.e. one Snellen drop) is
dependent on one’s baseline visual acuity and values of the other covariates in the








Intercept 1 3.7905 0.3759 3.0536   4.5273 101.66 <.0001
Gender 1 -0.1769 0.1838 -0.5372   0.1834 0.93 0.336
Baseline Snellen 1 0.1184 0.0435 0.0331   0.2037 7.4 0.0065
Prior treatment
(Y/N) 1 -0.13 0.1962 -0.5146   0.2547 0.44 0.5078
Treatment Group 1 0.5109 0.1926 0.1334   0.8885 7.04 0.008
Scale 1 1.3366 0.0678 1.2101   1.4762
Weibull Shape 1 0.7482 0.0379 0.6774   0.8264
Markov Model Results
The following tables show the benefits as obtained by the Markov model.  The effect
of PDT with verteporfin is shown for two outcomes, vision years gained and quality
adjusted life years gained.  There are also two levels of starting visual acuity for
treatment shown; one on a cohort with good vision (20/40), and one on a cohort with
poorer vision of 20/100.   Table 3 shows the estimated  benefits from the model.  The
0.89 vision year difference (approximate 95% CL; 0.22-1.4) suggests that those in
the treatment group would expect to spend an extra 325 days (10.8 months) above a
visual acuity level of 20/200 versus those in the placebo group over a 5-year period,
when treatment begins at a level of 20/40.  Likewise, the 0.17 QALY difference
(approximate 95% CL; 0.05 – 0.30) suggests that an extra 62 quality-adjusted days
(2 months) are gained by verteporfin therapy for the base case.
Table 3: Vision Years and Quality Adjusted Life Years (QALYs) for the Base Case: 5-
year time frame, cohort with baseline best corrected visual acuity=20/40
Placebo Verteporfin Difference (approximate 95% CL*)
Vision
Years 2.16 3.05 0.89 (0.22 - 1.40)
QALYs 2.21 2.38 0.17 (0.05 - 0.30)
*CL=Confidence LimitsCHE Discussion Paper 187  7
The following tables illustrate a series of one-way sensitivity analyses.  These
analyses demonstrate variations from the base-case regarding baseline visual acuity,
number of years of follow-up, discount rate and assumed extent of treatment effect.
In Table 4, it can be seen that the expected outcomes diminish as the cohort’s
baseline visual acuity decreases.  The incremental change (difference) is more
dramatic with vision years than QALYs, indicating that the expected relative decrease
in vision years is greater (as compared to QALYs) as the baseline visual acuity
worsens.  Treating a cohort with a baseline visual acuity of 20/160 (instead of 20/40)
yields 53% of the expected difference in QALYs (0.09/0.17 QALYS) over the base-
case, whereas the same cohort would expect only 27% of the expected difference in
vision years (0.24/0.89 vision years).
Table 4: Sensitivity Analysis on Baseline Visual Acuity
QALYs over a 5 year timeframe
Baseline VA Placebo Verteporfin Difference
20/40 2.21 2.38 0.17
20/64 2.06 2.16 0.10
20/100 2.00 2.10 0.10
20/160 1.92 2.01 0.09
Vision Years over a 5 year timeframe
Baseline VA Placebo Verteporfin Difference
20/40 2.16 3.05 0.89
20/64 1.8 2.62 0.82
20/100 1.22 1.86 0.64
20/160 0.42 0.66 0.24
In Table 5, the number of years of follow-up is clearly related to the anticipated
incremental difference for both measures, with increasing returns for greater follow-
up.  This table also indicates that over half of the gains predicted by the model
accrue after the trial period in the case of QALYs, and more than 80% accrue after
the trial period in the case of vision years. In effect, this increase in treatment benefit
with longer time horizons is mainly due to the continuation of efficacy gains
established during the trial period.
Table 5: Sensitivity Analysis on Number of years of Follow-up:
QALYs for a cohort with baseline best corrected
visual acuity=20/40
Yrs of Follow-up Placebo Verteporfin Difference
2 1.14 1.21 0.07
3 1.56 1.65 0.09
4 1.91 2.04 0.13
5 2.21 2.38 0.17
Vision Years for a cohort with baseline best
corrected visual acuity=20/40
Yrs of Follow-up Placebo Verteporfin Difference
2 1.62 1.77 0.15
3 1.96 2.39 0.43
4 2.11 2.8 0.69
5 2.16 3.05 0.89
The discount rate is varied in Table 6.  Varying the discount from 3% to 10% yields
74% of the expected difference for both outcomes (0.14/0.19 for QALYs, and
0.89/0.70 for vision years).8 Modelling the long-term benefits of PDT with verteporfin for AMD
Table 6: Sensitivity Analysis on Baseline Discount Rate
5-year timeframe, QALYs for a cohort with baseline
best corrected visual acuity=20/40
Discount Rate Placebo Verteporfin Difference
3% 2.21 2.40 0.19
5% 2.07 2.24 0.17
10% 1.88 2.02 0.14
5-year timeframe, Vision Years for a cohort with
baseline best corrected visual acuity=20/40
Discount Rate Placebo Verteporfin Difference
3% 2.16 3.05 0.89
5% 2.07 2.88 0.81
10% 1.94 2.64
0.70
In Table 7 the extent of the treatment effect is varied.  This reflects the number of
years that the model uses the hazard rate from the treatment group.  When the
assumed treatment effect is two years, the modelled treatment effect for those on
verteporfin follows the hazard predicted by the regression model for those on
verteporfin for two years, then follows that for the placebo group for three years.  If
the extent of effect is set to five years (as in the base case), the assumed effect of
treatment for those on verteporfin follows that predicted by the regression model for
those on verteporfin for the full five years.  In the case of QALYs, the treatment effect
duration of two years is 82% of that expected in the base-case (0.14/0.17), and in the
case of vision years the treatment effect duration of two years is 71% of the base
case (0.63/0.89). What this demonstrates is that modelled changes in the treatment
effect after the trial period has a relatively modest impact on the 5-year gain
estimates. Of far more significance is the choice of time horizon over which the trial
results are extrapolated (see Table 5 above).
Table 7: Sensitivity Analysis on Extent of Treatment Effect*
5 Year results on QALYs for a cohort with baseline best
corrected visual acuity=20/40
Extent of Effect Placebo Verteporfin Difference
2.0 Years 2.21 2.35 0.14
2.6 Years 2.21 2.36 0.15
3.2 Years 2.21 2.36 0.15
3.8 Years 2.21 2.37 0.16
4.4 Years 2.21 2.38 0.17
5.0 Years 2.21 2.38 0.17
5 year results on Vision Years for a cohort with baseline
best corrected visual acuity=20/40
Extent of Effect Placebo Verteporfin Difference
2.0 Years 2.16 2.78 0.63
2.6 Years 2.16 2.84 0.68
3.2 Years 2.16 2.89 0.73
3.8 Years 2.16 2.95 0.79
4.4 Years 2.16 3 0.84
5.0 Years 2.16 3.05 0.89
*After the specified time, the hazard rate for the treatment group (ie the treatment effect) is set
to be identical to the hazard rate for the placebo group. For example, extent of effect=2 years
assumes no difference in treatment and placebo rates of vision loss after the trial period;
extent of effect=5 years is the base case.CHE Discussion Paper 187   9
Discussion
The model described within this paper suggests that treating predominately classic,
subfoveal AMD lesions using PDT with verteporfin has a greater effect when initiated
at better levels of visual acuity.  Further, the anticipated gains are expected to
increase as follow-up increases.  At five years, a cohort with baseline visual acuity of
20/40 is projected to gain 0.89 vision years and 0.17 QALYs.
There is anecdotal evidence that clinicians are treating patients with fewer courses of
therapy than were administered in the trial  (i.e. 2-3 versus 5-6).  To the extent that
this is the case, any cost-effectiveness ratios resulting from calculations made using
the model presented here will be approximately halved – provided, of course, that
similar outcomes are observed.  However, without the benefit of further study it is not
possible to determine if outcomes would indeed be similar with fewer treatments.
There are several caveats to keep in mind with this work.  We have not considered
any side-effects that may occur from PDT with verteporfin treatment.  These side-
effects include visual disturbance (22.1% verteporfin and 15.5% placebo), injection
site adverse events (15.9% verteporfin and 5.8% placebo), infusion-related back pain
(2.5% verteporfin and 0% placebo), allergic reaction (2% verteporfin and 3.9%
placebo) and photosensitivity reactions (3.5% verteporfin and 0% placebo).  All side-
effects, with the exception of allergic reactions, were more prominent in the
verteporfin arm.  A total of 7 patients (1.7%) withdrew from treatment due to adverse
events.(Bressler, 2001, 198-207) While some of these events would surely impact on
quality of life, the relatively small number of withdrawals suggests that the overall
impact may have been modest.
Another caveat is that these results are applicable only to the situation where the eye
being treated is the better-seeing eye, has subfoveal CNV wherein the lesion
diagnosis is at least 50% Classic CNV.  Since AMD is a progressive, bilateral
disease the better-seeing eye will often be the second eye involved in the disease
process.  If, in clinical practice, the worse-seeing eye (the first eye involved with
AMD) is treated, the results shown here are probably too optimistic.  Further, if the
treatment is used outside the context of those with predominately classic, subfoveal
CNV, the results are less valuable and should be treated with caution.
The gains predicted by the model in the base case come largely as a result of
extending the time horizon beyond the trial period.  This should be kept in mind when
interpreting the results, and the findings should be treated with appropriate caution.
This is the best available evidence on which to base the model however.  The results
favour treatment over a range of assumptions.
Conclusion
Earlier treatment (i.e. treating eyes at less severe stages of disease) leads to more
favourable outcome estimates.  Consideration should be given to early detection and
treatment, particularly in the second eye to become involved.10 Modelling the long-term benefits of PDT with verteporfin for AMD
Appendix A
Since the modeling effort described here was completed, further follow-up data has
become available from the clinical trial upon which the model is based.  This data
suggests that those treated with PDT experience stabilization in their vision during
the third year.(TAP Study Group, 2001)  This three year follow-up data is not
controlled, however, because the trial was designed as a two-year follow-up study.
Thus the subsequent years of data do not have a placebo group comparison.
Nonetheless, this added information is felt to be of importance because it extends the
outcome experience of the treated group by 50% (from 2 years to 3 years).
This appendix describes a sensitivity analysis undertaken to try and understand the
possible effects of this new data on our modeling results.  Given that there is not
similar follow-up information from the control group, using this information requires
certain additional assumptions to be made.  There are at least two possibilities
regarding the implications of these results for the cost-effectiveness of the drug.
Under one scenario, the stabilization in vision in the treated group is a result of the
drug treatment, which would imply that the model we have used is too conservative
with regard to the effectiveness of the treatment.  Alternatively, the stabilization of
vision may be due to the natural disease process in the specific cohort being treated
in the trial, implying that we would have observed a similar effect if we could have
followed the placebo group for the additional year, making the effectiveness results
difficult to predict.  To model these two possibilities, we have undertaken two
sensitivity analyses.  In the first sensitivity analysis, we make the assumption that the
stabilization in vision is due to the effect of the drug.  For this analysis (sensitivity
analysis I) those in the treatment group have their visual function held constant after
two years, while those in the placebo continue to experience a decrease in visual
acuity as predicted by the Weibull hazard used in the model.  A second sensitivity
analysis has also been done where the assumption is that the stabilization in vision is
part of the natural history of the disease.  In this analysis (sensitivity analysis II), we
hold constant the visual loss in both groups (treated and placebo) after two years.
With both analyses we have extrapolated to a five year time-frame.
The results of this sensitivity analysis are shown in the table below.  There are two
sets of results, one for vision year gained, and one for QALY gained; both sets of
results are stratified by starting visual acuity (20/40 or 20/100).  Three scenarios are
shown: the base case, wherein the effects for both groups are extrapolated to five
years based on the two-year follow-up from the clinical trial; sensitivity analysis I,
where it is assumed that the treatment group experiences no further deterioration in
visual functioning after two years, and the placebo continues to lose vision at the rate
predicted by the model; and sensitivity analysis II, where it is assumed that the vision
in both groups stabilizes after two years.
In the vision year gained analysis, sensitivity analysis I suggests greater
effectiveness for all levels of starting visual acuity.  As with the main analysis the
effect is even greater when the cohort has better starting visual acuity.  Sensitivity
analysis II shows a more mixed set of results, but they are generally lower than the
base case.
Taken together, these scenarios suggest a range of effectiveness from 0.76 to 1.52
vision year gained over five years for those starting treatment at a visual acuity of
20/40, and a range of 0.64 to 1.14 vision years gained over five years for those
starting treatment at a visual acuity of 20/100.  The quality adjusted life year gained
analysis suggests, over a 5 year period, a range of 0.15 to 0.25 QALYs gained for
those with a starting visual acuity of 20/40, and 0.06 to 0.15 QALYs gained for thoseCHE Discussion Paper 187   11
starting at a visual acuity of 20/100.  This analysis shows that the benefit estimates
are sensitive to assumptions about the visual functioning after the end of the clinical
trial period.
Analysis of the three year data suggests that at least in one case (vision years
gained under sensitivity analysis II) that those starting at a worse level of visual
acuity may benefit more than those with better visual acuity.
This additional analysis has made use of additional follow-up data of the treatment
group from the clinical trial by undertaking a series of sensitivity analyses.  These
sensitivity analyses here reinforce the notion that treatment at higher visual acuity
levels may yield more efficient use of resources, but perhaps not in all cases.12 Modelling the long-term benefits of PDT with verteporfin for AMD
Appendix Table
Sensitivity Analysis Using 3 Year Data:
Vision Years Gained over a 5 year timeframe
  Base Case Sensitivity Analysis I Sensitivity Analysis II
  Placebo Treatment Difference Placebo Treatment Difference Placebo Treatment Difference
Cohort with
starting vision of
20/40 2.16 3.05 0.89 2.16 3.68 1.52 2.92 3.68 0.76
Cohort with
starting vision of
20/100 1.22 1.86 0.64 1.22 2.36 1.14 1.52 2.36 0.84
Sensitivity Analysis Using 3 Year Data:
QALYs Gained over a 5 year timeframe
  Base Case Sensitivity Analysis I Sensitivity Analysis II
  Placebo Treatment Difference Placebo Treatment Difference Placebo Treatment Difference
Cohort with
starting vision of
20/40 2.21 2.4 0.19 2.21 2.46 0.25 2.31 2.46 0.15
Cohort with
starting vision of
20/100 2.01 2.14 0.13 2.00 2.15 .15 2.09 2.15 0.06
Sensitivity Analysis I: Extrapolated to 5 years, VA constant after 2 years for Treated Group
Sensitivity Analysis II:Extrapolated to 5 years, VA constant after 2 years for Both Groups
Base Case is over a 5 year time frame for the indicated starting visual acuityCHE Discussion Paper 187   13
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